Laboratory of Animal Products Chemistry, Graduate School of Agricultural Science, Tohoku University, Sendai, Miyagi, Japan.
J Appl Microbiol. 2010 Sep;109(3):927-35. doi: 10.1111/j.1365-2672.2010.04719.x.
To identify and characterize a new adhesin-like protein of probiotics that show specific adhesion to human blood group A and B antigens.
Using the BIACORE assay, the adhesion of cell surface components obtained from four lactobacilli strains that adhered to blood group A and B antigens was tested. Their components showed a significant adhesion to A and B antigens when compared to the bovine serum albumin (BSA) control. The 1 mol l(-1) GHCl fraction extracted from Lactobacillus mucosae ME-340 contained a 29-kDa band (Lam29) using SDS-PAGE. The N-terminal amino acid sequence and homology analysis showed that Lam29 was 90% similar to the substrate-binding protein of the ATP-binding cassette (ABC) transporter from Lactobacillus fermentum IFO 3956. The complete nucleotide sequence (858 bp) of Lam29 was determined and encoded a protein of 285 amino acid residues. Phylogenetic analysis and multiple sequence alignments indicated this protein may be related to the cysteine-binding transporter.
The adhesion of ME-340 strain to blood group A and B antigens was mediated by Lam29 that is a putative component of ABC transporter as an adhesin-like protein.
Lactobacillus mucosae ME-340 expressing Lam29 may be useful for competitive exclusion of pathogens via blood group antigen receptors in the human gastrointestinal mucosa and in the development of new probiotic foods.
鉴定并描述一种对人血型 A 和 B 抗原具有特异性黏附作用的益生菌黏附素样蛋白。
利用 BIACORE 分析,测试了从 4 株黏附血型 A 和 B 抗原的乳杆菌中获得的细胞表面成分的黏附性。与牛血清白蛋白(BSA)对照相比,这些成分对 A 和 B 抗原表现出显著的黏附作用。使用 SDS-PAGE,从黏膜乳杆菌 ME-340 中提取的 1 mol l(-1) GHCl 级分含有 29 kDa 带(Lam29)。N 端氨基酸序列和同源性分析表明,Lam29 与发酵乳杆菌IFO 3956 的 ABC 转运体的底物结合蛋白有 90%的相似性。确定了 Lam29 的完整核苷酸序列(858 bp),并编码了 285 个氨基酸残基的蛋白质。系统发育分析和多重序列比对表明,该蛋白可能与半胱氨酸结合转运体有关。
ME-340 菌株对血型 A 和 B 抗原的黏附是由 Lam29 介导的,Lam29 是 ABC 转运体的一个假定组成部分,作为黏附素样蛋白。
表达 Lam29 的黏膜乳杆菌 ME-340 可能通过人胃肠道黏膜上的血型抗原受体对病原体具有竞争性排斥作用,并可用于开发新的益生菌食品。